| Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing drug candidates for immuno-inflammatory diseases. Co.'s pipeline of drug candidates that Co. is developing includes: ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; and ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, for the treatment of moderate to severe atopic dermatitis. Co. is also developing ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, as a potential treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. The ACRS YTD return is shown above.
The YTD Return on the ACRS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ACRS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACRS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.